$2.21
+0.02
(+0.91%)▲
Insights on Accuray Incorporated
Revenue is up for the last 2 quarters, 103.89M → 107.23M (in $), with an average increase of 3.1% per quarter
Netprofit is down for the last 4 quarters, 599.0K → -9.62M (in $), with an average decrease of 255.6% per quarter
1.63%
Downside
Day's Volatility :3.16%
Upside
1.56%
1.81%
Downside
52 Weeks Volatility :49.53%
Upside
48.6%
Period | Accuray Incorporated | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -21.22% | -0.7% | 0.0% |
6 Months | -22.34% | 6.6% | 0.0% |
1 Year | -26.26% | 3.7% | -1.5% |
3 Years | -57.56% | 14.0% | -21.8% |
Market Capitalization | 229.1M |
Book Value | $0.48 |
Earnings Per Share (EPS) | -0.14 |
PEG Ratio | 0.08 |
Wall Street Target Price | 8.75 |
Profit Margin | -3.25% |
Operating Margin TTM | 3.73% |
Return On Assets TTM | 0.01% |
Return On Equity TTM | -29.27% |
Revenue TTM | 447.5M |
Revenue Per Share TTM | 4.64 |
Quarterly Revenue Growth YOY | 16.8% |
Gross Profit TTM | 154.0M |
EBITDA | 5.1M |
Diluted Eps TTM | -0.14 |
Quarterly Earnings Growth YOY | -0.96 |
EPS Estimate Current Year | -0.08 |
EPS Estimate Next Year | 0.13 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | 0.01 |
What analysts predicted
Upside of 295.93%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 404.9M | ↑ 5.6% |
Net Income | -23.9M | ↓ 19.2% |
Net Profit Margin | -5.9% | ↑ 1.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 418.8M | ↑ 3.43% |
Net Income | -16.4M | ↓ 31.25% |
Net Profit Margin | -3.92% | ↑ 1.98% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 382.9M | ↓ 8.56% |
Net Income | 3.8M | ↓ 123.29% |
Net Profit Margin | 1.0% | ↑ 4.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 396.3M | ↑ 3.49% |
Net Income | -6.3M | ↓ 264.91% |
Net Profit Margin | -1.59% | ↓ 2.59% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 429.9M | ↑ 8.48% |
Net Income | -5.3M | ↓ 15.27% |
Net Profit Margin | -1.24% | ↑ 0.35% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 447.6M | ↑ 4.12% |
Net Income | -9.3M | ↑ 73.56% |
Net Profit Margin | -2.07% | ↓ 0.83% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 96.5M | ↓ 12.3% |
Net Income | -5.4M | ↑ 57.85% |
Net Profit Margin | -5.65% | ↓ 2.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 114.8M | ↑ 18.93% |
Net Income | -1.9M | ↓ 65.61% |
Net Profit Margin | -1.63% | ↑ 4.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 118.1M | ↑ 2.88% |
Net Income | 599.0K | ↓ 131.96% |
Net Profit Margin | 0.51% | ↑ 2.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 118.3M | ↑ 0.2% |
Net Income | -2.6M | ↓ 526.71% |
Net Profit Margin | -2.16% | ↓ 2.67% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 103.9M | ↓ 12.17% |
Net Income | -3.0M | ↑ 16.16% |
Net Profit Margin | -2.86% | ↓ 0.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 107.2M | ↑ 3.22% |
Net Income | -9.6M | ↑ 224.05% |
Net Profit Margin | -8.97% | ↓ 6.11% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 378.7M | ↓ 6.82% |
Total Liabilities | 330.1M | ↓ 8.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 438.2M | ↑ 15.7% |
Total Liabilities | 388.3M | ↑ 17.64% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 490.1M | ↑ 11.84% |
Total Liabilities | 427.3M | ↑ 10.04% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 480.1M | ↓ 2.04% |
Total Liabilities | 411.3M | ↓ 3.75% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 472.8M | ↓ 1.51% |
Total Liabilities | 419.7M | ↑ 2.04% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 479.2M | ↑ 1.35% |
Total Liabilities | 425.6M | ↑ 1.4% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 466.3M | ↓ 1.37% |
Total Liabilities | 419.4M | ↓ 0.07% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 468.8M | ↑ 0.52% |
Total Liabilities | 417.0M | ↓ 0.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 475.7M | ↑ 1.48% |
Total Liabilities | 421.0M | ↑ 0.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 479.2M | ↑ 0.73% |
Total Liabilities | 425.6M | ↑ 1.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 476.8M | ↓ 0.5% |
Total Liabilities | 425.9M | ↑ 0.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 476.4M | ↓ 0.1% |
Total Liabilities | 428.7M | ↑ 0.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.3M | ↓ 4923.95% |
Investing Cash Flow | 17.8M | ↓ 0.32% |
Financing Cash Flow | -27.5M | ↓ 49.66% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.6M | ↓ 261.7% |
Investing Cash Flow | -4.3M | ↓ 124.27% |
Financing Cash Flow | 28.5M | ↓ 203.72% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.5M | ↓ 95.04% |
Investing Cash Flow | -3.7M | ↓ 13.52% |
Financing Cash Flow | 26.7M | ↓ 6.24% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.5M | ↓ 2721.65% |
Investing Cash Flow | -2.4M | ↓ 35.65% |
Financing Cash Flow | -28.8M | ↓ 207.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.4M | ↓ 106.23% |
Investing Cash Flow | -4.7M | ↑ 96.62% |
Financing Cash Flow | -15.4M | ↓ 46.64% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.5M | ↓ 747.46% |
Investing Cash Flow | -12.7M | ↑ 168.84% |
Financing Cash Flow | -2.1M | ↓ 86.26% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 46.0K | ↓ 100.99% |
Investing Cash Flow | -1.3M | ↓ 8.88% |
Financing Cash Flow | -4.4M | ↓ 3195.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.0M | ↓ 39260.87% |
Investing Cash Flow | -1.5M | ↑ 20.6% |
Financing Cash Flow | 4.3M | ↓ 197.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 24.6M | ↓ 236.7% |
Investing Cash Flow | -1.9M | ↑ 23.79% |
Financing Cash Flow | -1.5M | ↓ 135.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.9M | ↓ 63.94% |
Investing Cash Flow | -8.0M | ↑ 320.01% |
Financing Cash Flow | -522.0K | ↓ 65.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.6M | ↓ 196.73% |
Investing Cash Flow | -1.1M | ↓ 86.31% |
Financing Cash Flow | -1.5M | ↑ 187.36% |
Sell
Neutral
Buy
Accuray Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Accuray Incorporated | -14.79% | -22.34% | -26.26% | -57.56% | -46.59% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Accuray Incorporated | NA | NA | 0.08 | -0.08 | -0.29 | 0.0 | NA | 0.48 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Accuray Incorporated | Buy | $229.1M | -46.59% | NA | -3.25% |
BlackRock Inc
Archon Capital Management LLC
Neuberger Berman Group LLC
Vanguard Group Inc
Royce & Associates, LP
Renaissance Technologies Corp
Accuray Incorporated’s price-to-earnings ratio stands at None
Read Moreaccuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.
Organization | Accuray Incorporated |
Employees | 1024 |
CEO | Ms. Suzanne Winter M.B.A. |
Industry | Health Technology |